BTIG analyst Thomas Shrader has maintained their bullish stance on GANX stock, giving a Buy rating on November 13.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thomas Shrader has given his Buy rating due to a combination of factors that highlight the potential of Gain Therapeutics’ innovative approach to treating diseases like Parkinson’s Disease and Gaucher’s Disease. The company’s strategy involves correcting mutant GCase and enhancing the transport of the wild-type enzyme, which is a promising method that could significantly impact disease treatment. Gain Therapeutics’ focus on identifying allosteric pockets to stabilize GCase in its active form is particularly noteworthy, as it could improve cellular health by ensuring proper enzyme function.
Furthermore, recent preclinical data presented at a major neuroscience conference demonstrated the efficacy of GT-02287 in modulating mitochondrial GCase, reducing mitochondrial stress, and enhancing neuronal survival. These findings add to the growing evidence supporting the therapeutic potential of GT-02287. With upcoming biomarker data expected soon, there is anticipation around the drug’s ability to clear aggregated substrates in lysosomes and reduce toxic alpha-synuclein levels, which could further validate the company’s approach and drive interest from potential partners.
In another report released on November 13, Roth MKM also reiterated a Buy rating on the stock with a $6.00 price target.
GANX’s price has also changed dramatically for the past six months – from $1.910 to $2.850, which is a 49.21% increase.